Beyond Intent: Addressing Diversity, Inclusion, and Equitable Participation in Clinical Trials for Patients and Your Business
Sponsored by ClinEco
Diversity, Inclusion, and Equitable participation (DI&E) are the cornerstones of a successful clinical trial and a thriving business. This need is further underscored by the proposed FDA Diverse and Equitable Participation in Clinical Trials (DEPICT) Act, which challenges our industry to go beyond intent and get real about ‘how’ we can make a meaningful difference.
Come and learn from our distinguished faculty how Pharmaceutical Companies, CROs, Vendors, and Health Care Providers are addressing this challenge to ensure patients are not denied potential life-changing treatments.
Key Questions to Discuss and to Consider:
• What are the risks of not shifting from intent to action (for Sponsor, Vendor, CRO and HCP)?
• What are the key challenges and how are you addressing these within your business?
• What role does effective oversight play in ultimate success?
• How will true success look like in clinical trials and across all aspects of the life science industry?
Privacy Policy
- Diversity, Inclusion, and Equitable participation (DI&E) are the cornerstones of a successful clinical trial and a thriving business. This need is further underscored by the proposed FDA Diverse and Equitable Participation in Clinical Trials (DEPICT) Act, which challenges our industry to go beyond intent and get real about ‘how’ we can make a meaningful difference. Come and learn from our distinguished faculty how Pharmaceutical Companies, CROs, Vendors, and Health Care Providers are addressing this challenge to ensure patients are not denied potential life-changing treatments.
- Proposed DEPICT act expectations
- Approaches to ensure effective recruitment and retention of under-represented participants
- How ClinEco helps select, compare, and partner with diverse organizations
